Table 1 Clinical and pathological characteristics of breast cancer patients.
From: Overexpression of RUNX2 promotes breast cancer multi-organ metastasis through stabilizing c-Myc
Characteristic | Non-Met. (%) | Met. (%) | P (χ2) |
|---|---|---|---|
Age | 0.1059 | ||
≤50 | 46 (70.7) | 19 (29.3) | |
>50 | 38 (58.4) | 29 (41.6) | |
ER status | 0.1482 | ||
Positive | 53 (68.8) | 24 (31.2) | |
Negative | 31 (56.4) | 24 (43.6) | |
PR status | 0.0707 | ||
Positive | 46 (71.9) | 18 (28.1) | |
Negative | 38 (55.9) | 30 (44.1) | |
HER2 status | 0.1809 | ||
Unamplified | 53 (59.6) | 36 (40.4) | |
Amplified | 31 (72.1) | 12 (27.9) | |
Ki-67 | 0.3857 | ||
Low | 41 (63.1) | 20 (33.9) | |
High | 37 (60.7) | 25 (67.6) | |
Missing | 0 (0.0) | 3 (100.0) | |
Molecular subtype | 0.3857 | ||
Luminal A | 21 (80.8) | 5 (19.2) | |
Luminal B | 29 (61.7) | 18 (38.3) | |
HER2 enriched | 15 (88.2) | 2 (11.8) | |
TNBC/BLBC | 19 (45.2) | 23 (54.8) | |
Pathologic grade | 0.0004 | ||
1‒2 | 51 (78.5) | 14 (21.5) | |
3 | 32 (48.5) | 34 (51.5) | |
Tumor stage | 0.0411 | ||
T1 | 14 (66.7) | 7 (33.3) | |
T2‒3 | 60 (60.6) | 39 (39.1) | |
T3 | 0 (0.0) | 4 (100.0) | |
Node stage | 0.0727 | ||
N0 | 44 (73.3) | 16 (26.7) | |
N1 | 19 (61.3) | 12 (38.7) | |
N2‒3 | 21 (51.2) | 20 (48.8) |
